Drug-eluting stent for left main coronary artery disease: The DELTA registry: A multicenter registry evaluating percutaneous coronary intervention versus coronary artery bypass grafting for left main treatment

Alaide Chieffo, Emanuele Meliga, Azeem Latib, Seung Jung Park, Yoshinobu Onuma, Piera Capranzano, Marco Valgimigli, Sanda Jegere, Raj R. Makkar, Igor F. Palacios, Young Hak Kim, Pawel E. Buszman, Tarun Chakravarty, Imad Sheiban, Roxana Mehran, Christoph Naber, Ronan Margey, Arvind Agnihotri, Sebastiano Marra, Davide CapodannoMartin B. Leon, Jeffrey W. Moses, Jean Fajadet, Thierry Lefevre, Marie Claude Morice, Andrejs Erglis, Corrado Tamburino, Ottavio Alfieri, Patrick W. Serruys, Antonio Colombo

Research output: Contribution to journalArticle

95 Citations (Scopus)

Abstract

Objectives: The aim of this study was to compare, in a large all-comers registry, major adverse cardiac and cerebrovascular events (MACCE) after percutaneous coronary intervention (PCI) with first-generation drug-eluting stents (DES) versus coronary artery bypass grafting (CABG) in unprotected left main coronary artery (ULMCA) stenosis. Background: Percutaneous coronary intervention with DES implantation in ULMCA has been shown to be a feasible and safe approach at midterm clinical follow-up. Methods: All consecutive patients with ULMCA stenosis treated by PCI with DES versus CABG were analyzed in this multinational registry. A propensity score analysis was performed to adjust for baseline differences in the overall cohort. Results: In total 2,775 patients were included: 1,874 were treated with PCI versus 901 with CABG. At 1,295 (interquartile range: 928 to 1,713) days, there were no differences, at the adjusted analysis, in the primary composite endpoint of death, cerebrovascular accidents, and myocardial infarction (MI) (adjusted hazard ratio [HR]: 1.11; 95% confidence interval [CI]: 0.85 to 1.42; p = 0.47), mortality (adjusted HR: 1.16; 95% CI: 0.87 to 1.55; p = 0.32), or composite endpoint of death and MI (adjusted HR: 1.25; 95% CI: 0.95 to 1.64; p = 0.11). An advantage of CABG over PCI was observed in the composite secondary endpoint of MACCE (adjusted HR: 1.64; 95% CI: 1.33 to 2.03; p <0.0001), driven exclusively by the higher incidence of target vessel revascularization with PCI. Conclusions: In our multinational all-comers registry, no difference was observed in the occurrence of death, cerebrovascular accidents, and MI between PCI and CABG. An advantage of CABG over PCI was observed in the incidence of MACCE, driven by the higher incidence of target vessel revascularization with PCI.

Original languageEnglish
Pages (from-to)718-727
Number of pages10
JournalJACC: Cardiovascular Interventions
Volume5
Issue number7
DOIs
Publication statusPublished - Jul 2012

Fingerprint

Drug-Eluting Stents
Percutaneous Coronary Intervention
Coronary Artery Bypass
Registries
Coronary Artery Disease
Confidence Intervals
Therapeutics
Coronary Stenosis
Myocardial Infarction
Incidence
Stroke
Propensity Score
Coronary Vessels
Mortality

Keywords

  • coronary artery bypass graft
  • drug-eluting stent
  • left main coronary artery disease
  • percutaneous coronary intervention

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Drug-eluting stent for left main coronary artery disease : The DELTA registry: A multicenter registry evaluating percutaneous coronary intervention versus coronary artery bypass grafting for left main treatment. / Chieffo, Alaide; Meliga, Emanuele; Latib, Azeem; Park, Seung Jung; Onuma, Yoshinobu; Capranzano, Piera; Valgimigli, Marco; Jegere, Sanda; Makkar, Raj R.; Palacios, Igor F.; Kim, Young Hak; Buszman, Pawel E.; Chakravarty, Tarun; Sheiban, Imad; Mehran, Roxana; Naber, Christoph; Margey, Ronan; Agnihotri, Arvind; Marra, Sebastiano; Capodanno, Davide; Leon, Martin B.; Moses, Jeffrey W.; Fajadet, Jean; Lefevre, Thierry; Morice, Marie Claude; Erglis, Andrejs; Tamburino, Corrado; Alfieri, Ottavio; Serruys, Patrick W.; Colombo, Antonio.

In: JACC: Cardiovascular Interventions, Vol. 5, No. 7, 07.2012, p. 718-727.

Research output: Contribution to journalArticle

Chieffo, A, Meliga, E, Latib, A, Park, SJ, Onuma, Y, Capranzano, P, Valgimigli, M, Jegere, S, Makkar, RR, Palacios, IF, Kim, YH, Buszman, PE, Chakravarty, T, Sheiban, I, Mehran, R, Naber, C, Margey, R, Agnihotri, A, Marra, S, Capodanno, D, Leon, MB, Moses, JW, Fajadet, J, Lefevre, T, Morice, MC, Erglis, A, Tamburino, C, Alfieri, O, Serruys, PW & Colombo, A 2012, 'Drug-eluting stent for left main coronary artery disease: The DELTA registry: A multicenter registry evaluating percutaneous coronary intervention versus coronary artery bypass grafting for left main treatment', JACC: Cardiovascular Interventions, vol. 5, no. 7, pp. 718-727. https://doi.org/10.1016/j.jcin.2012.03.022
Chieffo, Alaide ; Meliga, Emanuele ; Latib, Azeem ; Park, Seung Jung ; Onuma, Yoshinobu ; Capranzano, Piera ; Valgimigli, Marco ; Jegere, Sanda ; Makkar, Raj R. ; Palacios, Igor F. ; Kim, Young Hak ; Buszman, Pawel E. ; Chakravarty, Tarun ; Sheiban, Imad ; Mehran, Roxana ; Naber, Christoph ; Margey, Ronan ; Agnihotri, Arvind ; Marra, Sebastiano ; Capodanno, Davide ; Leon, Martin B. ; Moses, Jeffrey W. ; Fajadet, Jean ; Lefevre, Thierry ; Morice, Marie Claude ; Erglis, Andrejs ; Tamburino, Corrado ; Alfieri, Ottavio ; Serruys, Patrick W. ; Colombo, Antonio. / Drug-eluting stent for left main coronary artery disease : The DELTA registry: A multicenter registry evaluating percutaneous coronary intervention versus coronary artery bypass grafting for left main treatment. In: JACC: Cardiovascular Interventions. 2012 ; Vol. 5, No. 7. pp. 718-727.
@article{1be02f6f0cba47b9a1f804051afe426a,
title = "Drug-eluting stent for left main coronary artery disease: The DELTA registry: A multicenter registry evaluating percutaneous coronary intervention versus coronary artery bypass grafting for left main treatment",
abstract = "Objectives: The aim of this study was to compare, in a large all-comers registry, major adverse cardiac and cerebrovascular events (MACCE) after percutaneous coronary intervention (PCI) with first-generation drug-eluting stents (DES) versus coronary artery bypass grafting (CABG) in unprotected left main coronary artery (ULMCA) stenosis. Background: Percutaneous coronary intervention with DES implantation in ULMCA has been shown to be a feasible and safe approach at midterm clinical follow-up. Methods: All consecutive patients with ULMCA stenosis treated by PCI with DES versus CABG were analyzed in this multinational registry. A propensity score analysis was performed to adjust for baseline differences in the overall cohort. Results: In total 2,775 patients were included: 1,874 were treated with PCI versus 901 with CABG. At 1,295 (interquartile range: 928 to 1,713) days, there were no differences, at the adjusted analysis, in the primary composite endpoint of death, cerebrovascular accidents, and myocardial infarction (MI) (adjusted hazard ratio [HR]: 1.11; 95{\%} confidence interval [CI]: 0.85 to 1.42; p = 0.47), mortality (adjusted HR: 1.16; 95{\%} CI: 0.87 to 1.55; p = 0.32), or composite endpoint of death and MI (adjusted HR: 1.25; 95{\%} CI: 0.95 to 1.64; p = 0.11). An advantage of CABG over PCI was observed in the composite secondary endpoint of MACCE (adjusted HR: 1.64; 95{\%} CI: 1.33 to 2.03; p <0.0001), driven exclusively by the higher incidence of target vessel revascularization with PCI. Conclusions: In our multinational all-comers registry, no difference was observed in the occurrence of death, cerebrovascular accidents, and MI between PCI and CABG. An advantage of CABG over PCI was observed in the incidence of MACCE, driven by the higher incidence of target vessel revascularization with PCI.",
keywords = "coronary artery bypass graft, drug-eluting stent, left main coronary artery disease, percutaneous coronary intervention",
author = "Alaide Chieffo and Emanuele Meliga and Azeem Latib and Park, {Seung Jung} and Yoshinobu Onuma and Piera Capranzano and Marco Valgimigli and Sanda Jegere and Makkar, {Raj R.} and Palacios, {Igor F.} and Kim, {Young Hak} and Buszman, {Pawel E.} and Tarun Chakravarty and Imad Sheiban and Roxana Mehran and Christoph Naber and Ronan Margey and Arvind Agnihotri and Sebastiano Marra and Davide Capodanno and Leon, {Martin B.} and Moses, {Jeffrey W.} and Jean Fajadet and Thierry Lefevre and Morice, {Marie Claude} and Andrejs Erglis and Corrado Tamburino and Ottavio Alfieri and Serruys, {Patrick W.} and Antonio Colombo",
year = "2012",
month = "7",
doi = "10.1016/j.jcin.2012.03.022",
language = "English",
volume = "5",
pages = "718--727",
journal = "JACC: Cardiovascular Interventions",
issn = "1936-8798",
publisher = "Elsevier Inc.",
number = "7",

}

TY - JOUR

T1 - Drug-eluting stent for left main coronary artery disease

T2 - The DELTA registry: A multicenter registry evaluating percutaneous coronary intervention versus coronary artery bypass grafting for left main treatment

AU - Chieffo, Alaide

AU - Meliga, Emanuele

AU - Latib, Azeem

AU - Park, Seung Jung

AU - Onuma, Yoshinobu

AU - Capranzano, Piera

AU - Valgimigli, Marco

AU - Jegere, Sanda

AU - Makkar, Raj R.

AU - Palacios, Igor F.

AU - Kim, Young Hak

AU - Buszman, Pawel E.

AU - Chakravarty, Tarun

AU - Sheiban, Imad

AU - Mehran, Roxana

AU - Naber, Christoph

AU - Margey, Ronan

AU - Agnihotri, Arvind

AU - Marra, Sebastiano

AU - Capodanno, Davide

AU - Leon, Martin B.

AU - Moses, Jeffrey W.

AU - Fajadet, Jean

AU - Lefevre, Thierry

AU - Morice, Marie Claude

AU - Erglis, Andrejs

AU - Tamburino, Corrado

AU - Alfieri, Ottavio

AU - Serruys, Patrick W.

AU - Colombo, Antonio

PY - 2012/7

Y1 - 2012/7

N2 - Objectives: The aim of this study was to compare, in a large all-comers registry, major adverse cardiac and cerebrovascular events (MACCE) after percutaneous coronary intervention (PCI) with first-generation drug-eluting stents (DES) versus coronary artery bypass grafting (CABG) in unprotected left main coronary artery (ULMCA) stenosis. Background: Percutaneous coronary intervention with DES implantation in ULMCA has been shown to be a feasible and safe approach at midterm clinical follow-up. Methods: All consecutive patients with ULMCA stenosis treated by PCI with DES versus CABG were analyzed in this multinational registry. A propensity score analysis was performed to adjust for baseline differences in the overall cohort. Results: In total 2,775 patients were included: 1,874 were treated with PCI versus 901 with CABG. At 1,295 (interquartile range: 928 to 1,713) days, there were no differences, at the adjusted analysis, in the primary composite endpoint of death, cerebrovascular accidents, and myocardial infarction (MI) (adjusted hazard ratio [HR]: 1.11; 95% confidence interval [CI]: 0.85 to 1.42; p = 0.47), mortality (adjusted HR: 1.16; 95% CI: 0.87 to 1.55; p = 0.32), or composite endpoint of death and MI (adjusted HR: 1.25; 95% CI: 0.95 to 1.64; p = 0.11). An advantage of CABG over PCI was observed in the composite secondary endpoint of MACCE (adjusted HR: 1.64; 95% CI: 1.33 to 2.03; p <0.0001), driven exclusively by the higher incidence of target vessel revascularization with PCI. Conclusions: In our multinational all-comers registry, no difference was observed in the occurrence of death, cerebrovascular accidents, and MI between PCI and CABG. An advantage of CABG over PCI was observed in the incidence of MACCE, driven by the higher incidence of target vessel revascularization with PCI.

AB - Objectives: The aim of this study was to compare, in a large all-comers registry, major adverse cardiac and cerebrovascular events (MACCE) after percutaneous coronary intervention (PCI) with first-generation drug-eluting stents (DES) versus coronary artery bypass grafting (CABG) in unprotected left main coronary artery (ULMCA) stenosis. Background: Percutaneous coronary intervention with DES implantation in ULMCA has been shown to be a feasible and safe approach at midterm clinical follow-up. Methods: All consecutive patients with ULMCA stenosis treated by PCI with DES versus CABG were analyzed in this multinational registry. A propensity score analysis was performed to adjust for baseline differences in the overall cohort. Results: In total 2,775 patients were included: 1,874 were treated with PCI versus 901 with CABG. At 1,295 (interquartile range: 928 to 1,713) days, there were no differences, at the adjusted analysis, in the primary composite endpoint of death, cerebrovascular accidents, and myocardial infarction (MI) (adjusted hazard ratio [HR]: 1.11; 95% confidence interval [CI]: 0.85 to 1.42; p = 0.47), mortality (adjusted HR: 1.16; 95% CI: 0.87 to 1.55; p = 0.32), or composite endpoint of death and MI (adjusted HR: 1.25; 95% CI: 0.95 to 1.64; p = 0.11). An advantage of CABG over PCI was observed in the composite secondary endpoint of MACCE (adjusted HR: 1.64; 95% CI: 1.33 to 2.03; p <0.0001), driven exclusively by the higher incidence of target vessel revascularization with PCI. Conclusions: In our multinational all-comers registry, no difference was observed in the occurrence of death, cerebrovascular accidents, and MI between PCI and CABG. An advantage of CABG over PCI was observed in the incidence of MACCE, driven by the higher incidence of target vessel revascularization with PCI.

KW - coronary artery bypass graft

KW - drug-eluting stent

KW - left main coronary artery disease

KW - percutaneous coronary intervention

UR - http://www.scopus.com/inward/record.url?scp=84864029323&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864029323&partnerID=8YFLogxK

U2 - 10.1016/j.jcin.2012.03.022

DO - 10.1016/j.jcin.2012.03.022

M3 - Article

C2 - 22814776

AN - SCOPUS:84864029323

VL - 5

SP - 718

EP - 727

JO - JACC: Cardiovascular Interventions

JF - JACC: Cardiovascular Interventions

SN - 1936-8798

IS - 7

ER -